Optibiotix Health Share Discussion Threads

[owenmo] 08/3/2017 07:30

Spring has sprung, eh?

[woodaldo] 08/3/2017 07:30

Excellent news today, 50% profits and also like this bit
"Discussions are progressing with corporate partners for the manufacture and supply of products containing LPLDL® in the US, Asian and other international markets." Getting ready to go global. Our patience is finally starting to pay off folks..Good luck all.

[bobdown2] 08/3/2017 07:30

This as well as Tata should really start the ball rolling.

[scotty1] 08/3/2017 07:27

And remember no material seller in the market now so could really start to motor ;))

[qs99] 08/3/2017 07:24

That really does IMO put the cat amongst the pigeons...would be good to know some estimates of numbers that this could generate and time frames, maybe a new broker note will appear after such a material RNS? DYOR etc

[scotty1] 08/3/2017 07:19

Yeah should be a good day,news now starting to flow,just need diamond to post now that he told us so ;))

[rafboy] 08/3/2017 07:17

Blue day ahead, good news.

[scotty1] 08/3/2017 07:09

Nice :))))))))

[parob] 08/3/2017 07:07

Amazing news. Manufacturer of LP-LDL sorted.50% of profits!Distributor agreements to follow next in the lead up to the Vitafoods expo IMO.

[someuwin] 08/3/2017 07:05

OptiBiotix Health plc

("OptiBiotix" or the "Company")



European manufacturing, supply and profit sharing agreement



OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol,
diabetes and skin care, announces that it has entered into a manufacturing and supply agreement with Sacco S.r.l., ("Sacco"). The agreement grants Sacco an exclusive licence to manufacture and supply OptiBiotix's cholesterol reducing strain, LPLDL®, in Europe in return for 50% of the profit with a minimum price per kilogramme to secure against discounting.



Sacco, founded in 1934, is one of Europe's leading probiotic manufacturers and supplies raw ingredients, including some of the world's best selling probiotic strains, to over 2,500 businesses across Europe. Under the terms of the agreement, Sacco will promote and expand the supply of LPLDL® throughout Europe on the maximum possible scale bringing it to the attention of as many buyers as possible.



LPLDL® will be supplied by Sacco as a raw ingredient to food, beverage, consumer healthcare and pharmaceutical partners to be incorporated into a wide range of final formulations and presentations. These will be subject to separate license agreements creating the opportunity for multiple revenue streams at different points in the value chain arising from:-



· Profit share of the sale of the strain as an ingredient by Sacco

· Royalties from the sale of higher value white label formulations, and branded products from consumer healthcare and pharmaceutical partners



This agreement is the first step in a business to business (B2B) strategy of bringing OptiBiotix's science together with partner's brand portfolio and market reach to serve consumer healthcare and pharmaceutical markets around the world.



Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of a manufacturing, supply, and profit sharing agreement with Sacco, one of Europe's leading suppliers of probiotics ingredients. We chose Sacco due to their industry reputation, extensive European network and track record in building sales for what have become some of the world's best selling probiotic strains. We believe that OptiBiotix's strong supporting science, and growing industry awareness of our LPLDL® cholesterol and blood pressure reducing strain, has created a high level of interest in using LPLDL® as a functional component in a wide range of consumer healthcare and pharmaceutical products. We believe working with Sacco, and similar partners around the world, provide the best opportunity of building LPLDL® into a global brand. Discussions are progressing with corporate partners for the manufacture and supply of products containing LPLDL® in the US, Asian and other international markets."

[whl2] 08/3/2017 07:05

sure is, 50% profit !

[judijudi] 08/3/2017 07:02

That's an earner! :)

[whl2] 07/3/2017 22:49

I've heard they drink at Diamond's local !

[joyjoy13] 07/3/2017 20:30

Good to see BUY recommended signal generated....

Britishbulls - Technical analysis of OPTI.L with candlesticks

[colinzeal] 07/3/2017 20:24

Do it Elrico - that post is hilarious.

[1bokke] 07/3/2017 20:14

Diamond, so I've read your post for the third time now... Nope. You know Gekko went to jail in the end right?

[parob] 07/3/2017 20:13

HIGHLIGHTS FROM PROBIOTA 2017 IN BERLIN

Is pharma interest in probiotics a challenge or opportunity?



Great to see no sign whatsoever of the seller today. I can sense some more blue days this week.

[elrico] 07/3/2017 19:49

I don't have the heart scotty :))

[whl2] 07/3/2017 19:45

Optibiotix has some of the best people in there fields, my friend is a very clever person but it's surprising what triple will say once they have had 8 gin and tonics! DIAMOND.


I presume the l is pronounced silently !!

[scotty1] 07/3/2017 19:30

Got to be in with a chance elrico :))

[elrico] 07/3/2017 19:28

Diamond - Seriously dude, edit your post. I am really fighting with myself here....the urge to nominate you for share price BBM competition is very strong :-)

[scotty1] 07/3/2017 19:20

Diamond do you just invest in local business to were you live ,cos i was just thinking you must have to travel a long ways to see the employees in their local pubs on a nightly basis pmsl.

[elrico] 07/3/2017 19:19

Diamond - you do realise you have been paying michaelmouses bar bill for the past 12 months, right!